A 24-month, muti-center, randomized, open-label, non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled everolimus with reduced cyclosporine versus 3.0g mycophenolate mofetil with standard dose cyclosporine in de novo heart transplant recipients.

Trial Profile

A 24-month, muti-center, randomized, open-label, non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled everolimus with reduced cyclosporine versus 3.0g mycophenolate mofetil with standard dose cyclosporine in de novo heart transplant recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil; Steroids
  • Indications Heart transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation
    • 16 Sep 2015 Results presented at the 17th Congress of the European Society for Organ Transplantation
    • 09 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top